Tae Min Kim

Tae Min Kim is a hematologic oncologist specializing in diffuse large B cell lymphoma and the molecular and clinical characteristics of DLBCL in East Asian patients. His research has addressed whether Western clinical trial outcomes are generalizable to Korean and East Asian DLBCL populations, including pharmacogenomic differences in rituximab metabolism and response. He has contributed to Korean multicenter clinical trials of novel agents in aggressive lymphomas and investigated the molecular subtype distribution and genetic landscape of DLBCL in East Asian cohorts.